Ultomiris for Paroxysmal Nocturnal Hemoglobinuria

ULTOMIRIS (ravulizumab-cwvz , Alexion Pharmaceuticals, Inc.)

Indications: treatment of adult patients with paroxysmal nocturnal hemoglobinuria

Dosage: intravenous infusion only

• 40 kg ≤ X< 60 kg – 2,400mg leading, 3,000 mg maintenance

• 60kg ≤ X < 100kg – 2,700mg leading, 3,300mg maintenance

• 100kg ≤  X – 3,000mg leading, 3,600 maintenance

Contraindications: patients with unresolved Neisseria Meningitidis infection.

​Click here for more prescribing information